Quick Answer
NEKTAR THERAPEUTICS reported Cash And Cash Equivalents At Carrying Value of $15.12 million for the year ending 2025.
- NEKTAR THERAPEUTICS showed a decrease of -65.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from NEKTAR THERAPEUTICS's annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), NEKTAR THERAPEUTICS's Cash And Cash Equivalents At Carrying Value has declined by 90.3%.
- Historical annual values: Fiscal year 2025: $15.12 million | Fiscal year 2024: $44.25 million | Fiscal year 2023: $35.28 million | Fiscal year 2022: $88.23 million | Fiscal year 2021: $25.22 million | Fiscal year 2020: $198.96 million | Fiscal year 2019: $96.36 million | Fiscal year 2018: $194.91 million | Fiscal year 2017: $4.76 million | Fiscal year 2016: $59.64 million | Fiscal year 2015: $55.57 million | Fiscal year 2014: $12.37 million | Fiscal year 2013: $39.07 million | Fiscal year 2012: $25.44 million | Fiscal year 2011: $15.31 million | Fiscal year 2010: $17.76 million | Fiscal year 2009: $49.60 million | Fiscal year 2008: $155.58 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: